Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial

OBJECTIVES: The primary endpoint of the pivotal phase III study of infliximab (IFX) s.c. demonstrated non-inferiority of s.c. to i.v. IFX, based on 28-joint DAS-CRP (DAS28-CRP) improvement at week (W) 22 (NCT03147248). This post-hoc analysis investigated whether numerical differences in efficacy out...

Descripción completa

Detalles Bibliográficos
Autores principales: Constantin, Arnaud, Caporali, Roberto, Edwards, Christopher J, Fonseca, João Eurico, Iannone, Florenzo, Keystone, Edward, Schulze-Koops, Hendrik, Kwon, Taek, Kim, Seungmin, Yoon, SangWook, Kim, Dong-Hyeon, Park, Gahee, Yoo, Dae Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393429/
https://www.ncbi.nlm.nih.gov/pubmed/36534825
http://dx.doi.org/10.1093/rheumatology/keac689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393429/
https://www.ncbi.nlm.nih.gov/pubmed/36534825
http://dx.doi.org/10.1093/rheumatology/keac689

Ejemplares similares